Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.

Abstract: This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest. The method comprises constructing the library in the presence of an inhibitor of poxvirus assembly, e.g., rifampicin, which allows construction of libraries with higher complexity and diversity than previous methods.

Abstract: This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, e.g., vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest. The method comprises constructing the library in the presence of an inhibitor of poxvirus assembly, e.g., rifampicin, which allows construction of libraries with higher complexity and diversity than previous methods.

Abstract: This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, e.g., vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest. The method comprises constructing the library in the presence of an inhibitor of poxvirus assembly, e.g., rifampicin, which allows construction of libraries with higher complexity and diversity than previous methods.

Abstract: This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, e.g., vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest. The method comprises constructing the library in the presence of an inhibitor of poxvirus assembly, e.g., rifampicin, which allows construction of libraries with higher complexity and diversity than previous methods.

Abstract: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.

Abstract: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.

Abstract: The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.

Abstract: A transition device for providing a smooth corner of a pair of angular oriented interconnected windshields on a boat, the boat having a forward facing or front windshield and a side facing windshield, both the windshields being mounted in a formed aluminum molding. The transition device comprises a first element attached to the molding of the forward facing windshield at an upper end of the joint and terminating at the joint in a ball and a second element attached to the molding of the side facing windshield at the upper end of the joint and terminating in a socket. The ball and the socket are shaped and sized to fit together to form a smooth transition at the upper end of the joint so that the corner joint appears to have a ball and socket joint.

Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

Abstract: The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.

Abstract: A method of sealing a plug with a food sauce dispensing cartridge enables leak proof operation of the dispensing cartridge at the site of the plug. The plug, having a circumferential edge, is positioned within the dispensing cartridge and oriented such that the edge is adjacent to the cartridge sidewall. A layer of hot melt adhesive is then applied to the circumferential edge and flows into a gap created between the plug and the cartridge sidewall at a sideseam formed by an overlap region of the cartridge sidewall. The hot melt adhesive subsequently bonds the plug to the cartridge sidewall and prevents food sauce from moving past the circumferential edge of the plug and out of a containment region.